drugset / Trial / NCT00283179

Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia

NCT00283179

Phase 3 Completed 83 enrolled Taiwan Otsuka Pharm. Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy, safety and tolerability of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder with risperidone as an active control.

Timeline

Start
2004-03
Primary completion
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 15 mg
Subject Risperidone Other / unclassified 6 mg